secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2022-08-18T23:59:59+00:00
Accession:  0001193125-22-223699
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts partial clinical hold on Curis's TakeAim Lymphoma study of emavusertib
--------------------------------------------------------------------------------

- FDA lifted partial clinical hold on TakeAim Lymphoma Phase 1/2 study; enrollment to resume Q3 2022.
- Partial hold on TakeAim Leukemia study remains under FDA Division of Hematologic Malignancies 1.
- Hold lifted after FDA agreement on rhabdomyolysis management and enrollment of ≥9 patients at 200 mg emavusertib plus ibrutinib.
- Preliminary clinical data update from TakeAim Lymphoma expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000119312522223699/0001193125-22-223699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000119312522223699/d356879d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-223699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer